|
|
|
| Clinical research of combination of memantine and butylphthaliden in the treatment of patinta with vascular dementia |
1.The First Clinical Medical College of Wenzhou Medical University, Wenzhou, 325035; 2.Department of Geriatrics, Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou, 325000; 3.Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015
|
|
| Cite this article: |
|
PAN Rongrong1,2,ZHOU Longshou2, et al. Clinical research of combination of memantine and butylphthaliden in the treatment of patinta with vascular dementia[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(10): 756-758.
|
|
|
Abstract Objective: To observe the curative effect and safety of combination of memantine and butylphthalide in the treatment of vascular dementia (VaD), the improvement of the cognitive function and behavioral capacity. Methods: Forty cases with VaD were randomly divided into 2 groups: one group treated with memantine and butylphthalide, the other group treated with memantine. MMSE scale and ADL scale of 2 groups were assessed and compared the pre-treatment with the treatment in 3 months, 6 months later. A comparative study was made to evalate the curative effects and side effects between 2 groups. Results: After treating with memantine and butylphthaliden for 3 months and 6 months, the ADL scores were (25.2±5.4) and (23.2±5.6) respectively, MMSE scores were (18.8±4.4) and (20.1±4.8) respectively. After treatment with memantine for 3 months and 6 months, the ADL scores were (26.6±5.9) and (25.4±6.1) respectively, MMSE scores were (18.1±4.9) and (18.9±4.7) respectively. The data compared pre-treatment with the two groups had statistical significance (P<0.05). The scores of MMSE and ADL after 6 months treatment between two groups have statistical significance (P<0.05). No serious adverse events was recorded during treatment. Conclusion: Combination of memantine and butylphthalide can markedly ameliorate the cognitive function and behavioral abilities in patients with vascular dementia. Its combination with butylphthalide is superior to its single use with high safety.
|
|
Received: 24 October 2013
|
| |
|
|
|
[1]李梨, 周岐新, 石京山. 血管性痴呆研究概况[J]. 中国老年学杂志, 2005, 25(10): 1269-1271.
[2]Tariot PN. Contemporary issues in the treatment of Alzheim-ers’ disease: angible benefits of current therapies[J]. J Clin Psychiatry, 2006, 67(Suppl 3): 15-22.
[3]Erkinjuntti T, Roman G, Gauthier S, et al. Emerging thera-pies for vascular dementia and vascular cognitive impairment[J]. Stroke, 2004, 35(4): 1010-1017.
[4]全国脑血管会议. 各类脑血管疾病诊断要点[J]. 中华神经科杂志, 1996, 29(6): 379-380.
[5]Nagata K, Sato M, Satoh Y, et al. Hemodynamic aspects of Alzheimer’s disease[J]. Ann NY Acad Sci, 2002, 977: 391-402.
[6]Kumar S. Memantine: pharmacological properties and clinical uses[J]. Neurol India, 2004, 52(3): 307-309.
[7]何雨, 金玉芬, 张昱. 美金刚对血管性痴呆大鼠海马N-甲基-D-天冬氨酸-2β受体的影响[J]. 中华老年心脑血管病杂志, 2007, 9(11): 771-774.
[8]熊杰, 冯亦璞. 丁苯酞对局灶性脑缺血过程中线粒体损伤的保护作用[J]. 药学学报, 2000, 35(6): 408-412.
[9]孙乐羽. 丁苯酞软胶囊治疗血管性痴呆的临床疗效[J]. 中国老年学杂志, 2013, 33(8): 3967-3969.
[10]侯德仁, 陈坤, 王艳, 等. 丁苯酞治疗血管性痴呆的疗效和作用机制[J]. 南方医科大学学报, 2009, 29(3): 574-578.
[11]Berthier ML, Green C, Lars JP, et al. Memantine and con-straint-induced aphasia therapy in chronic poststroke apha-sia[J]. Ann Neurol, 2009, 65(7): 577-585.
[12]祝锡聪. 美金刚在治疗脑卒中后认知障碍中的疗效观察[J]. 山西医药杂志, 2012, 41(1): 59-61.
[13]Emre M, Mecocci P, Stender K. Pooled analyses on cogni-tive effects of memantine in patients with moderate to severe Alzheimer’s disease[J]. J Alzheimers Dis, 2008, 14(2):193-199.
[14]吴娟. 丁苯酞对血管性痴呆患者认知功能的改善作用[J].重庆医学, 2012, 41(6): 571-572. |
|
|
|
2014, Vol. 44 
